Regenera receives ethics approval for second clinical trial

By Renate Krelle
Wednesday, 20 October, 2004

Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.

Visagen is a preservative free formulation of the steroid triamcinolone acetonide.

The trials will be conducted in conjunction with the Singapore Eye Research Institute, an arm of the Singapore National Eye Centre.

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Content from other channels on our network

Food waste in Australian hospitals and aged care homes — can AI help?

Legislation introduced to improve private health choice and transparency

WA healthcare professionals gain workplace-specific courses

Why physical device security is becoming a patient privacy issue in health care

InterSystems Honoured with Four 2026 Best in KLAS Awards

Liquid metal to 'harvest' clean hydrogen from water

Epson makes progress with sustainability plans and initiatives in Australia and New Zealand

Sustainable wastewater treatment achieved for urban areas

'Brownfielding' increases to meet metal demand

NSW to exceed energy storage targets

Cyber risk is rising faster than Australian manufacturers can respond

Fortescue commissions first battery electric locomotives

Electric actuation: a gamechanger for upstream processes

Government seeks input on wind and transmission infrastructure

Additive manufacturing unlocks power for space and defence missions